BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Reuters

27 Mar

BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

March 27 (Reuters) - Regulus Therapeutics Inc RGLS.O:

REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH COHORT OF PATIENTS
REGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHS
REGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025

Source text: ID:nPnc8pndpa

Further company coverage: RGLS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522375477"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522375477\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522375477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522375477","market":"nz","top_or_hot":-1,"title":"BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease</title></head><body><p><span>March 27 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a> <span>RGLS.O</span>:</p><ul><li><p>REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE <a href=\"https://laohu8.com/S/MAD.AU\">$(MAD.AU)$</a> CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)</p></li><li><p>REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PATIENTS</p></li><li><p>REGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHS</p></li><li><p>REGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025</p></li></ul><p>Source text: <span>ID:nPnc8pndpa</span></p><p>Further company coverage: <span>RGLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-27 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease</title></head><body><p><span>March 27 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a> <span>RGLS.O</span>:</p><ul><li><p>REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE <a href=\"https://laohu8.com/S/MAD.AU\">$(MAD.AU)$</a> CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)</p></li><li><p>REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PATIENTS</p></li><li><p>REGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHS</p></li><li><p>REGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025</p></li></ul><p>Source text: <span>ID:nPnc8pndpa</span></p><p>Further company coverage: <span>RGLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGLS","symbol_name":"Regulus Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA088:1","article_id":"2522375477","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522375477","pubTimestamp":1743073716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney DiseaseMarch 27 (Reuters) - Regulus Therapeutics Inc RGLS.O:REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGLS":"Regulus Therapeutics Inc","BK4139":"生物科技"},"translate_title":"BRIEF-Regulus完成Farabursen治疗常染色体显性多囊肾病的1B期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLS":0.9},"content_text":"BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney DiseaseMarch 27 (Reuters) - Regulus Therapeutics Inc RGLS.O:REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH COHORT OF PATIENTSREGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHSREGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025Source text: ID:nPnc8pndpaFurther company coverage: RGLS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}